Clinical trial
A Phase I Study of Triapine® in Combination With Irinotecan in Refractory Tumors
NCT00084877 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Triapine® in Combination With Irinotecan in Refractory Tumors
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2004
- Completion date
- Not reported
- Enrollment
- 36 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
unspecified adult solid tumor, protocol specific